These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19668461)

  • 1. Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy.
    Friedlaender MH; Protzko E
    Clin Ophthalmol; 2007 Mar; 1(1):3-10. PubMed ID: 19668461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite) solution in the treatment of ocular infections.
    Utine CA
    Clin Ophthalmol; 2011; 5():801-9. PubMed ID: 21750614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin.
    Bowman LM; Si E; Pang J; Archibald R; Friedlaender M
    J Ocul Pharmacol Ther; 2009 Apr; 25(2):133-9. PubMed ID: 19284320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis.
    Abelson M; Protzko E; Shapiro A; Garces-Soldana A; Bowman L
    Clin Ophthalmol; 2007 Jun; 1(2):177-82. PubMed ID: 19668507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis.
    Protzko E; Bowman L; Abelson M; Shapiro A;
    Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3425-9. PubMed ID: 17652708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of Azithromycin Ophthalmic 1% Solution (AzaSite(®)) for the Treatment of Ocular Infections.
    Opitz DL; Harthan JS
    Ophthalmol Eye Dis; 2012; 4():1-14. PubMed ID: 23650453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
    Abelson MB; Heller W; Shapiro AM; Si E; Hsu P; Bowman LM;
    Am J Ophthalmol; 2008 Jun; 145(6):959-65. PubMed ID: 18374301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacodynamic properties of azithromycin in a kinetics-of-kill model and implications for bacterial conjunctivitis treatment.
    Dorfman MS; Wagner RS; Jamison T; Bell B; Stroman DW
    Adv Ther; 2008 Mar; 25(3):208-17. PubMed ID: 18369536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness, tolerability and safety of azithromycin 1% in DuraSite for acute bacterial conjunctivitis.
    McLean S; Sheikh A
    Patient Prefer Adherence; 2010 May; 4():69-76. PubMed ID: 20517467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular pharmacokinetics of AzaSite Xtra-2% azithromycin formulated in a DuraSite delivery system.
    Si EC; Cheung PS; Bowman L; Hosseini K
    Curr Eye Res; 2009 Jun; 34(6):485-91. PubMed ID: 19899983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of effectiveness and tolerance of treatment with azithromycin 1.5% eye drops in bacterial conjunctivitis].
    Ambroziak AM; Szaflik JP; Hapunik A
    Klin Oczna; 2009; 111(1-3):46-9. PubMed ID: 19517846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azithromycin in DuraSite for the treatment of blepharitis.
    Luchs J
    Clin Ophthalmol; 2010 Jul; 4():681-8. PubMed ID: 20689782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic resistance of bacterial pathogens isolated from the conjunctiva in the Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study (2009-2021).
    Asbell PA; Sanfilippo CM; DeCory HH
    Diagn Microbiol Infect Dis; 2024 Jan; 108(1):116069. PubMed ID: 37918187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotics for trachoma.
    Evans JR; Solomon AW; Kumar R; Perez Á; Singh BP; Srivastava RM; Harding-Esch E
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD001860. PubMed ID: 31554017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AzaSite® inhibits Staphylococcus aureus and coagulase-negative Staphylococcus biofilm formation in vitro.
    Wu EC; Kowalski RP; Romanowski EG; Mah FS; Gordon YJ; Shanks RM
    J Ocul Pharmacol Ther; 2010 Dec; 26(6):557-62. PubMed ID: 21029017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation.
    Akpek EK; Vittitow J; Verhoeven RS; Brubaker K; Amar T; Powell KD; Boyer JL; Crean C
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):433-9. PubMed ID: 19857105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbiological efficacy of 3-day treatment with azithromycin 1.5% eye-drops for purulent bacterial conjunctivitis.
    Denis F; Chaumeil C; Goldschmidt P; Delval L; Pouliquen P; Cochereau I; Chainier D; De Barbeyrac B
    Eur J Ophthalmol; 2008; 18(6):858-68. PubMed ID: 18988154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical semifluorinated alkane-based azithromycin suspension for the management of ocular infections.
    Agarwal P; Craig JP; Krösser S; Eickhoff K; Swift S; Rupenthal ID
    Eur J Pharm Biopharm; 2019 Sep; 142():83-91. PubMed ID: 31195132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limitations of current antibiotics for the treatment of bacterial conjunctivitis.
    Karpecki P; Paterno MR; Comstock TL
    Optom Vis Sci; 2010 Nov; 87(11):908-19. PubMed ID: 20838353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.
    Haas W; Gearinger LS; Hesje CK; Sanfilippo CM; Morris TW
    Adv Ther; 2012 May; 29(5):442-55. PubMed ID: 22644963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.